[Federal Register: November 17, 2003 (Volume 68, Number 221)]
[Notices]               
[Page 64901-64902]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr17no03-101]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-04-06]

 
Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the CDC Reports 
Clearance Officer on (404) 498-1210.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Send comments to Anne O'Connor, CDC 
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, 
Atlanta, GA 30333. Written comments should be received within 60 days 
of this notice.
    Proposed Project: Potential Reproductive and Neurological Effects 
of Exposure to Acrylamide--NEW--The National Institute for Occupational 
Safety and Health (NIOSH), Centers for Disease Control and Prevention 
(CDC).
    The mission of the National Institute for Occupational Safety and 
Health (NIOSH) is to promote safety and health at work for all people 
through research and prevention. Consistent with this mission, NIOSH is 
undertaking a study of the reproductive and neurobehavioral effects of 
the occupational exposure to acrylamide. Acrylamide workers and control 
workers (N = 100 per group) will be recruited from manufacturing, end-
user and non-exposed settings. Exposure will be characterized by 
acrylamide hemoglobin, adduct and urinary metabolite levels, ambient 
area, personal air, and dermal sampling. Reproductive effects will be 
evaluated by examining semen quality, sperm DNA integrity, reproductive 
hormone levels, and prostate specific antigen (PSA) levels.
    Neurobehavioral effects will be assessed using sensation-tactile, 
postual stability, grooved pegboard, and simple reaction time tests. 
Two questionnaires will be administered on one occasion. Questionnaire 
information will be collected concurrently to augment test 
interpretation, adjust for potential confounders and covariates during 
regression analysis, correlate specific jobs and job activities with 
exposure measurements, and for validation purposes. Findings from this 
study will clarify if the adverse reproductive effects observed in 
animal studies are also present in acrylamide-exposed workers, and if 
preclinical neurobehavioral deficits are present at acrylamide doses 
currently considered to be within safe limits.
    This study is scheduled for implementation in late 2003 and 2004. 
There are no costs to respondents.

----------------------------------------------------------------------------------------------------------------
                                                                     Number of     Average burden/
               Survey questionnaire                  Number of       responses/     response  (in   Total burden
                                                    respondents      respondent        hours)        (in hrs.)
----------------------------------------------------------------------------------------------------------------
 Medical & Reproductive History Questionnaire....       200                    1        13/60            43
 Occupational History Questionnaire..............       200                    1        34/60           113
 Non-participant Questionnaire...................        50                    1         2/60             2
                                                                                                  --------------
      Total......................................  .............  ...............  ..............       158
----------------------------------------------------------------------------------------------------------------



[[Page 64902]]

    Dated: November 10, 2003.
James D. Seligman,
Chief Information Officer, Office of the Chief Operations Officer, 
Centers for Disease Control and Prevention.
[FR Doc. 03-28605 Filed 11-14-03; 8:45 am]

BILLING CODE 4163-18-P